Indomethacin and its effect on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus

M. V. Betkerur, T. F. Yeh, K. Miller, R. J. Glasser, R. S. Pildes

研究成果: 雜誌貢獻文章同行評審

73 引文 斯高帕斯(Scopus)

摘要

In the course of a double-blind trial of intravenous indomethacin therapy in premature infants with patent ductus arteriosus, renal function and urinary kallikrein were studied in 21 infants following one dose of either saline placebo or indomethacin. Ten infants were assigned to the control group and 11 were in the indomethacin group. Significantly lower urine output, fraction excretion of sodium, fraction excretion of chloride, and urinary kallikrein were noted by 45%, 59%, 63%, and 51%, respectively, in the indomethacin group as compared to the control group. There was a concomitant decrease in serum sodium concentration (P<.05) at 24 hours following indomethacin therapy. No significant difference in glomerular filtration rate was seen between the control group and the indomethacin-treated infants.

原文英語
頁(從 - 到)99-102
頁數4
期刊Pediatrics
68
發行號1
出版狀態已發佈 - 十一月 9 1981
對外發佈

ASJC Scopus subject areas

  • 兒科、圍產兒和兒童健康

指紋

深入研究「Indomethacin and its effect on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus」主題。共同形成了獨特的指紋。

引用此